You need to enable JavaScript to run this app.
An official website of the United States government
An official website of the United States government
mobile navigation
Home
Search Catalog
Participating Resources
CCDI Studies
CCDI Resource & Datasets
Childhood Cancer Clinical Data Commons
Metadata Files
Molecular Targets Platform
Accessing CCDI Data (PDF)
About
About CCDI Data Catalog
Contribute to the CCDC
Glossary
Site Updates
User Guide (PDF)
CCDI Hub
Home
Search Catalog
Participating Resources
CCDI Studies
CCDI Resource & Datasets
Childhood Cancer Clinical Data Commons
Metadata Files
Molecular Targets Platform
Accessing CCDI Data (PDF)
About
About CCDI Data Catalog
Contribute to the CCDC
Glossary
Site Updates
User Guide (PDF)
CCDI Hub
Documentation Search
Home
Search Catalog
In vitro prednisolone resistance signature in MLL-rearranged infant ALL
In vitro prednisolone resistance signature in MLL-rearranged infant ALL
Data Resource:
GEO
Point of Contact:
Jill Spijkers-Hagelstein
,
j.hagelstein@erasmusmc.nl
Project
About This Dataset
Acute Lymphoblastic Leukemia (ALL) in infants (<1 year of age) is characterized by a high incidence of MLL translocations which is associated with a poor prognosis. Contributing to this poor prognosis is cellular drug resistance, especially to glucocorticoids like prednisolone. Although in vitro prednisolone resistance mechanisms have been proposed in pediatric ALL, it has never been studied in MLL-rearranged infant ALL, which are highly resistant to glucocorticoids in vitro and in vivo.
Core Data Elements
Case Sex
Not Reported ()
Case Age At Diagnosis
0 to 4 years ()
Case Race
Not Reported ()
Case Ethnicity
Not Reported ()
Case Disease Diagnosis
Acute Lymphoblastic Leukemia ()
Case Tumor Site
Peripheral Blood ()
Additional Data Elements
GEO STUDY IDENTIFIER
GSE32962
GSE32962
Published In
https://doi.org/10.1038/leu.2011.388
https://doi.org/10.1038/leu.2011.388